Unlike previous SGs‐focused studies,[20, 27, 28, 29, 30, 31] our work identifies a diabetes‐specific axis where ALKBH5‐G3BP1 blocks p53‐dependent repression of SLC7A11, thereby preserving glutathione synthesis and GPX4 activity. Here, TP53 is linked to diabetes mellitus.